NIH R01 · 2024
PROJECT SUMMARY Toxicities of treating human papilloma virus-related (HPV+) oropharyngeal squamous cell carcinomas (OPSCCs) with radiation plus cisplatin create lifelong disabilities in survivors of this increasingly common cancer. Reducing radiation doses and cisplatin use for HPV+ OPSCC is impeded by difficulty distinguishing a subset of cases with high recurrence risk, and the mechanisms of therapy resistance in such patients are unclear. These knowledge gaps contribute to both overtreating easily curable patients and ineffective therapy for high-risk cases. Opportunity to overcome these barriers arose from our finding that the HPV+ OPSCCs predisposed to recurrence upregulate a master…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.